Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$14.40
-2.0%
$10.67
$6.36
$47.45
$1.64B1.171.66 million shs3.60 million shs
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
$20.51
-2.9%
$22.07
$13.22
$54.08
$1.18B-1.87859,487 shs982,048 shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$22.19
-2.2%
$22.37
$18.53
$51.61
$1.42B1.13926,861 shs2.03 million shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$5.16
-12.7%
$8.14
$3.50
$14.30
$243.38MN/A375,623 shs298,218 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-2.04%+13.39%+25.87%+19.70%-53.46%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-2.93%-5.87%-19.76%-0.10%-61.35%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-2.25%-30.09%+1.93%-21.76%-42.36%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-12.69%-43.67%-49.95%+17.54%+515,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.783 of 5 stars
4.51.00.00.01.63.30.0
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
1.9929 of 5 stars
3.51.00.00.02.51.70.6
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.8365 of 5 stars
4.61.00.00.02.62.50.0
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.07
Buy$45.54216.24% Upside
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
3.00
Buy$76.50272.99% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
3.10
Buy$65.00192.92% Upside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZYBT, VERA, DYN, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/3/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/2/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00 ➝ $34.00
6/2/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.00
6/2/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $85.00
5/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$46.00
5/12/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $75.00
5/9/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $38.00
5/9/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.00
5/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.00
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$1.49 per shareN/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$9.77 per shareN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$1.94 per shareN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$189.75M1.28N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/6/2025 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%8/14/2025 (Estimated)
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A

Latest ZYBT, VERA, DYN, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/8/2025Q1 2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
5/8/2025Q1 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.75-$0.81-$0.06-$0.81N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
17.02
17.02
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/A
27.63
27.63
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.17
13.76
13.76
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
91.78%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million80.63 millionOptionable
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
13657.34 million51.86 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4063.77 million49.58 millionOptionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
27847.17 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$14.40 -0.30 (-2.04%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$14.46 +0.05 (+0.38%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$20.51 -0.62 (-2.93%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$20.60 +0.09 (+0.46%)
As of 08:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$22.19 -0.51 (-2.25%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$22.22 +0.02 (+0.11%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$5.16 -0.75 (-12.69%)
As of 06/9/2025 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.